142 related articles for article (PubMed ID: 24594238)
21. Identification of Compound Heterozygous Variants in LRP4 Demonstrates That a Pathogenic Variant outside the Third β-Propeller Domain Can Cause Sclerosteosis.
Huybrechts Y; Boudin E; Hendrickx G; Steenackers E; Hamdy N; Mortier G; Martínez Díaz-Guerra G; Bracamonte MS; Appelman-Dijkstra NM; Van Hul W
Genes (Basel); 2021 Dec; 13(1):. PubMed ID: 35052419
[TBL] [Abstract][Full Text] [Related]
22. An Additional Lrp4 High Bone Mass Mutation Mitigates the Sost-Knockout Phenotype in Mice by Increasing Bone Remodeling.
Hendrickx G; Boudin E; Mateiu L; Yorgan TA; Steenackers E; Kneissel M; Kramer I; Mortier G; Schinke T; Van Hul W
Calcif Tissue Int; 2024 Feb; 114(2):171-181. PubMed ID: 38051321
[TBL] [Abstract][Full Text] [Related]
23. The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis.
Yavropoulou MP; Xygonakis C; Lolou M; Karadimou F; Yovos JG
Hormones (Athens); 2014; 13(4):323-37. PubMed ID: 25555179
[TBL] [Abstract][Full Text] [Related]
24. Targeted deletion of Sost distal enhancer increases bone formation and bone mass.
Collette NM; Genetos DC; Economides AN; Xie L; Shahnazari M; Yao W; Lane NE; Harland RM; Loots GG
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14092-7. PubMed ID: 22886088
[TBL] [Abstract][Full Text] [Related]
25. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.
Loots GG; Kneissel M; Keller H; Baptist M; Chang J; Collette NM; Ovcharenko D; Plajzer-Frick I; Rubin EM
Genome Res; 2005 Jul; 15(7):928-35. PubMed ID: 15965026
[TBL] [Abstract][Full Text] [Related]
26. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease.
Balemans W; Patel N; Ebeling M; Van Hul E; Wuyts W; Lacza C; Dioszegi M; Dikkers FG; Hildering P; Willems PJ; Verheij JB; Lindpaintner K; Vickery B; Foernzler D; Van Hul W
J Med Genet; 2002 Feb; 39(2):91-7. PubMed ID: 11836356
[TBL] [Abstract][Full Text] [Related]
27. Sclerostin deficiency in humans.
van Lierop AH; Appelman-Dijkstra NM; Papapoulos SE
Bone; 2017 Mar; 96():51-62. PubMed ID: 27742500
[TBL] [Abstract][Full Text] [Related]
28. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts.
Sutherland MK; Geoghegan JC; Yu C; Winkler DG; Latham JA
Bone; 2004 Aug; 35(2):448-54. PubMed ID: 15268896
[TBL] [Abstract][Full Text] [Related]
29. A novel biallelic splice-site variant in the LRP4 gene causes sclerosteosis 2.
Bukowska-Olech E; Sowińska-Seidler A; Szczałuba K; Jamsheer A
Birth Defects Res; 2020 May; 112(9):652-659. PubMed ID: 32286743
[TBL] [Abstract][Full Text] [Related]
30. Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis.
Robinson MK; Caminis J; Brunkow ME
Drug Discov Today; 2013 Jul; 18(13-14):637-43. PubMed ID: 23579167
[TBL] [Abstract][Full Text] [Related]
31. Sclerostin and skeletal health.
Sharifi M; Ereifej L; Lewiecki EM
Rev Endocr Metab Disord; 2015 Jun; 16(2):149-56. PubMed ID: 25669441
[TBL] [Abstract][Full Text] [Related]
32. Sclerostin: a novel target for intervention in the treatment of osteoporosis.
Lewiecki EM
Discov Med; 2011 Oct; 12(65):263-73. PubMed ID: 22031665
[TBL] [Abstract][Full Text] [Related]
33. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.
Brunkow ME; Gardner JC; Van Ness J; Paeper BW; Kovacevich BR; Proll S; Skonier JE; Zhao L; Sabo PJ; Fu Y; Alisch RS; Gillett L; Colbert T; Tacconi P; Galas D; Hamersma H; Beighton P; Mulligan J
Am J Hum Genet; 2001 Mar; 68(3):577-89. PubMed ID: 11179006
[TBL] [Abstract][Full Text] [Related]
34. Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST).
Sevetson B; Taylor S; Pan Y
J Biol Chem; 2004 Apr; 279(14):13849-58. PubMed ID: 14739291
[TBL] [Abstract][Full Text] [Related]
35. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.
van Bezooijen RL; Papapoulos SE; Löwik CW
J Endocrinol Invest; 2005; 28(8 Suppl):15-7. PubMed ID: 16323824
[TBL] [Abstract][Full Text] [Related]
36. Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia.
Kim SJ; Bieganski T; Sohn YB; Kozlowski K; Semënov M; Okamoto N; Kim CH; Ko AR; Ahn GH; Choi YL; Park SW; Ki CS; Kim OH; Nishimura G; Unger S; Superti-Furga A; Jin DK
Hum Genet; 2011 May; 129(5):497-502. PubMed ID: 21221996
[TBL] [Abstract][Full Text] [Related]
37. SOST is a target gene for PTH in bone.
Keller H; Kneissel M
Bone; 2005 Aug; 37(2):148-58. PubMed ID: 15946907
[TBL] [Abstract][Full Text] [Related]
38. Serum Dickkopf 1 levels in sclerostin deficiency.
van Lierop AH; Moester MJ; Hamdy NA; Papapoulos SE
J Clin Endocrinol Metab; 2014 Feb; 99(2):E252-6. PubMed ID: 24302746
[TBL] [Abstract][Full Text] [Related]
39. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
Winkler DG; Sutherland MK; Geoghegan JC; Yu C; Hayes T; Skonier JE; Shpektor D; Jonas M; Kovacevich BR; Staehling-Hampton K; Appleby M; Brunkow ME; Latham JA
EMBO J; 2003 Dec; 22(23):6267-76. PubMed ID: 14633986
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
